Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $14.3B | $14.0B | $13.0B | $12.2B | $11.9B | $13.1B | $14.0B | $11.6B | $11.3B | $10.4B | $9.6B | $8.7B | $6.0B | $5.8B | $5.7B | $5.5B | $5.0B | $4.7B | $4.5B | $4.1B | $3.6B |
| Bruttoergebnis | $4.0B | $3.7B | $3.6B | $3.4B | $3.7B | $5.0B | $5.0B | $3.3B | $3.2B | $3.5B | $3.2B | $2.9B | $2.2B | $2.2B | $2.2B | $2.3B | $2.1B | $2.0B | $1.9B | $1.7B | $1.5B |
| Bruttomarge % | 27.9% | 26.8% | 27.9% | 27.7% | 31.3% | 38.0% | 35.4% | 28.1% | 28.0% | 33.2% | 33.0% | 33.5% | 36.6% | 38.3% | 39.7% | 41.0% | 41.9% | 42.0% | 41.6% | 41.6% | 42.6% |
| Betriebsergebnis (EBIT) | $1.6B | $1.5B | $1.1B | $726M | $1.4B | $3.0B | $2.4B | $1.3B | $1.3B | $1.4B | $1.3B | $1.0B | $910M | $991M | $1.0B | $948M | $979M | $936M | $843M | $777M | $697M |
| Operative Marge % | 11.3% | 10.9% | 8.3% | 6.0% | 12.1% | 23.2% | 17.5% | 11.5% | 11.7% | 13.1% | 13.6% | 11.6% | 15.1% | 17.1% | 18.1% | 17.1% | 19.6% | 19.9% | 18.7% | 19.1% | 19.4% |
| Jahresüberschuss | $1.0B | $876M | $746M | $418M | $1.3B | $2.4B | $1.6B | $824M | $884M | $1.3B | $732M | $437M | $511M | $574M | $583M | $520M | $558M | $543M | $464M | $477M | $432M |
| Nettomarge % | 7.0% | 6.3% | 5.7% | 3.4% | 10.8% | 18.1% | 11.1% | 7.1% | 7.8% | 12.2% | 7.6% | 5.0% | 8.5% | 9.9% | 10.3% | 9.4% | 11.2% | 11.6% | 10.3% | 11.7% | 12.0% |
| EBITDA | — | $2.0B | $1.8B | $1.3B | $2.0B | $3.7B | $3.3B | $2.1B | $2.1B | $1.8B | $1.8B | $1.6B | $1.2B | $1.2B | $1.3B | $1.2B | $1.2B | $1.1B | $1.0B | $990M | $853M |
| Ergebnis je Aktie (EPS) | $12.09 | $10.46 | $8.84 | $4.77 | $13.96 | $24.38 | $15.88 | $8.35 | $8.61 | $12.21 | $7.02 | $4.34 | $5.92 | $6.25 | $5.99 | $5.11 | $5.30 | $4.98 | $4.10 | $3.93 | $3.24 |
| Ausstehende Aktien (Mio.) | — | 84M | 84M | 88M | 92M | 98M | 98M | 99M | 103M | 104M | 104M | 101M | 86M | 92M | 97M | 102M | 105M | 109M | 113M | 121M | 133M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für LH. /companies/us/LH
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms